Consequently, directing therapeutic interventions towards the LIF axis may emerge as a promising approach to enhance the effectiveness of immune checkpoint inhibitor (ICI) therapy in patients with PD-L1 positive breast cancer. This evidence concerns the gene CD274 and breast carcinoma.